NYR.ASX: Phase I Clinical Trial Dosing Update No 3

Phase I Clinical Trial Dosing Update No 3

Stock	Nyrada Inc (NYR.ASX)
Release Time	21 May 2025, 9:48 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Nyrada Provides Phase I Clinical Trial Dosing Update

Key Points

Safety Review Committee approved progression to next cohort
Preclinical data shows NYR-BI03 provides neuroprotection and cardioprotection
Final Phase I trial readouts expected in Q3 2025

Full Summary

Nyrada Inc. has provided an update on its Phase I clinical trial of lead drug candidate NYR-BI03, a small-molecule, first-in-class drug for neuroprotection and cardioprotection indications. The company has confirmed that the Safety Review Committee (SRC) has reviewed cumulative safety and pharmacokinetic data from the first, second, and third cohorts in the clinical trial, and has raised no issues, enabling the trial to progress to the fourth cohort. Nyrada has also provided an overview of the preclinical data for NYR-BI03, which has shown statistically significant neuroprotective and cardioprotective effects in various studies, including stroke, coronary heart disease, and traumatic brain injury models. The company expects to report final Phase I trial readouts in the third quarter of the 2025 calendar year and will provide regular updates throughout the trial.